These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1228 related articles for article (PubMed ID: 33590936)

  • 1. Genetic and epigenetic factors associated with increased severity of Covid-19.
    Yildirim Z; Sahin OS; Yazar S; Bozok Cetintas V
    Cell Biol Int; 2021 Jun; 45(6):1158-1174. PubMed ID: 33590936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human genetic basis of severe or critical illness in COVID-19.
    Ji XS; Chen B; Ze B; Zhou WH
    Front Cell Infect Microbiol; 2022; 12():963239. PubMed ID: 36204639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human genetic basis of coronavirus disease 2019.
    Deng H; Yan X; Yuan L
    Signal Transduct Target Ther; 2021 Sep; 6(1):344. PubMed ID: 34545062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry.
    Ragia G; Manolopoulos VG
    Pharmacogenomics; 2020 Dec; 21(18):1311-1329. PubMed ID: 33243086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Hypothesis and Pharmacogenetics Side of Renin-Angiotensin-System in COVID-19.
    Gemmati D; Tisato V
    Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32899439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and Epigenetic Diversity of Protein Molecules Related to SARSCoV- 2 Entry: Where We Are and Where We Should Go?
    Zhu S; Chen F; Li X; Zhang Y; Wang X; Luan C
    Curr Protein Pept Sci; 2022; 23(2):70-76. PubMed ID: 35105286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity.
    Huang SW; Wang SF
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variants in ACE2; potential influences on virus infection and COVID-19 severity.
    Bakhshandeh B; Sorboni SG; Javanmard AR; Mottaghi SS; Mehrabi MR; Sorouri F; Abbasi A; Jahanafrooz Z
    Infect Genet Evol; 2021 Jun; 90():104773. PubMed ID: 33607284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable Clinical Manifestations of COVID-19: Viral and Human Genomes Talk.
    Imani-Saber Z; Vaseghi H; Mahdian M; Safari F; Ghadami M
    Iran J Allergy Asthma Immunol; 2020 Oct; 19(5):456-470. PubMed ID: 33463113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional prediction and comparative population analysis of variants in genes for proteases and innate immunity related to SARS-CoV-2 infection.
    Klaassen K; Stankovic B; Zukic B; Kotur N; Gasic V; Pavlovic S; Stojiljkovic M
    Infect Genet Evol; 2020 Oct; 84():104498. PubMed ID: 32771700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Updated Review on the Role of Single Nucleotide Polymorphisms in COVID-19 Disease Severity: A Global Aspect.
    Ng JW; Chong ETJ; Lee PC
    Curr Pharm Biotechnol; 2022; 23(13):1596-1611. PubMed ID: 35034591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE2, TMPRSS2, and Furin variants and SARS-CoV-2 infection in Madrid, Spain.
    Torre-Fuentes L; Matías-Guiu J; Hernández-Lorenzo L; Montero-Escribano P; Pytel V; Porta-Etessam J; Gómez-Pinedo U; Matías-Guiu JA
    J Med Virol; 2021 Feb; 93(2):863-869. PubMed ID: 32691890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes.
    Debnath M; Banerjee M; Berk M
    FASEB J; 2020 Jul; 34(7):8787-8795. PubMed ID: 32525600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients.
    Verma S; Abbas M; Verma S; Khan FH; Raza ST; Siddiqi Z; Ahmad I; Mahdi F
    Infect Genet Evol; 2021 Jul; 91():104801. PubMed ID: 33676010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Science Underlying COVID-19: Implications for the Cardiovascular System.
    Liu PP; Blet A; Smyth D; Li H
    Circulation; 2020 Jul; 142(1):68-78. PubMed ID: 32293910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of ACE2 Gene Variants with the Severity of COVID-19 Disease-A Prospective Observational Study.
    Sienko J; Marczak I; Kotowski M; Bogacz A; Tejchman K; Sienko M; Kotfis K
    Int J Environ Res Public Health; 2022 Oct; 19(19):. PubMed ID: 36231922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 multifaceted interaction with the human host. Part II: Innate immunity response, immunopathology, and epigenetics.
    Beacon TH; Su RC; Lakowski TM; Delcuve GP; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2331-2354. PubMed ID: 32936531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of angiotensin-converting enzyme 2 and proteases in COVID-19 patients: A potential role of cellular FURIN in the pathogenesis of SARS-CoV-2.
    Drak Alsibai K
    Med Hypotheses; 2020 Oct; 143():109893. PubMed ID: 32512290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
    Hosoki K; Chakraborty A; Sur S
    J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.